Imunon
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1982-01-01
- Employees
- 33
- Market Cap
- $16.7M
- Website
- http://imunon.com
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Imunon
- Target Recruit Count
- 74
- Registration Number
- NCT06283459
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸DM Clinical Research, Philadelphia, Pennsylvania, United States
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Imunon
- Target Recruit Count
- 50
- Registration Number
- NCT05739981
- Locations
- 🇺🇸
Johns Hopkins Medicine SKCCC, Baltimore, Maryland, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
- Conditions
- Interventions
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Imunon
- Target Recruit Count
- 130
- Registration Number
- NCT03393884
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Mitchell Cancer Institute (University of South Alabama), Mobile, Alabama, United States
🇺🇸Gynecologic Oncology Associates (Hoag Hospital), Newport Beach, California, United States
Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Imunon
- Registration Number
- NCT02850419
- Locations
- 🇨🇿
Inst. of Radiation Oncology Hospital Na Bulovce, Prague, Czechia
🇮🇹Fondazione Del Piemonte Per L'Oncologia - Irccs Candiolo, Candiolo, Italy
🇮🇱Rambam Health Care Campus, Haifa, Israel
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Imunon
- Target Recruit Count
- 18
- Registration Number
- NCT02480374
- Locations
- 🇺🇸
University of Alabama Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Washington Univ. in St. Louis/Barnes Jewish Hospital, St. Louis, Missouri, United States
🇺🇸Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Imunon
- Target Recruit Count
- 554
- Registration Number
- NCT02112656
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
🇨🇳302 Military Hospital of China, Beijing, China
🇨🇳Peking University First Hospital, Beijing, China
MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Imunon
- Registration Number
- NCT01640847
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
- Conditions
- Interventions
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Imunon
- Target Recruit Count
- 2
- Registration Number
- NCT01464593
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Cleveland Clinic Hospital, Cleveland, Ohio, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
- Conditions
- Interventions
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Imunon
- Target Recruit Count
- 17
- Registration Number
- NCT00826085
- Locations
- 🇺🇸
Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Southeastern Regional Medical Center, Newnan, Georgia, United States
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Imunon
- Target Recruit Count
- 701
- Registration Number
- NCT00617981
- Locations
- 🇹ðŸ‡
Siriraj Hospital, Bangkok, Thailand
🇨🇳Sun Yat-Sen University Cancer Center, Guangzhou, China
🇺🇸Mayo Clinic - Jacksonville, Florida, Jacksonville, Florida, United States